Current experimental approaches are using the Ep-CAM promoter to control the expression of therapeutic genes (Gires et al, 2004), and short interfering RNA for the silencing of Ep-CAM expression, which resulted in a 35–80% decrease in proliferation of breast cancer cell lines (Osta et al, 2004). This evidence concerns the gene EPCAM and breast cancer.